Evenity
Biological
UCB SA
Total Payments
$32,583
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $32,583 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $32,583 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ROMOSOZUMAB TREATMENT IN POSTMENOPAUSAL CHINESE WOMEN WITH OSTEOPOROSIS | UCB SA | $32,583 | 0 |
Top Doctors Receiving Payments for Evenity
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Durham, NC | $32,583 | 1 |
About Evenity
Evenity is a biological associated with $32,583 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is UCB SA.
Payment data is available from 2024 to 2024. In 2024, $32,583 was paid across 1 transactions to 0 doctors.
The most common payment nature for Evenity is "Unspecified" ($32,583, 100.0% of total).
Evenity is associated with 1 research study, including "A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ROMOSOZUMAB TREATMENT IN POSTMENOPAUSAL CHINESE WOMEN WITH OSTEOPOROSIS" ($32,583).